KR20030019902A - Liquid preparations for internal use - Google Patents

Liquid preparations for internal use Download PDF

Info

Publication number
KR20030019902A
KR20030019902A KR1020020050409A KR20020050409A KR20030019902A KR 20030019902 A KR20030019902 A KR 20030019902A KR 1020020050409 A KR1020020050409 A KR 1020020050409A KR 20020050409 A KR20020050409 A KR 20020050409A KR 20030019902 A KR20030019902 A KR 20030019902A
Authority
KR
South Korea
Prior art keywords
extract
acid
sodium
liquid formulation
hydrochloride
Prior art date
Application number
KR1020020050409A
Other languages
Korean (ko)
Inventor
오츠카시게노리
야마다히로유키
오카다미노루
무라타미사오
카네코테츠오
이마모리카츠미
Original Assignee
에스에스 세야쿠 가부시키 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스에스 세야쿠 가부시키 가이샤 filed Critical 에스에스 세야쿠 가부시키 가이샤
Publication of KR20030019902A publication Critical patent/KR20030019902A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/51Gentianaceae (Gentian family)
    • A61K36/515Gentiana

Abstract

PURPOSE: To provide an oral solution preparation that can retain the efficacy of the preparation for a long period of time because the active components in the sialid extract are preserved stably for a long period of time. CONSTITUTION: The oral solution preparation includes the sialid extract as the active components and has a pH adjusted to 4-7.

Description

내복 액상 제제 {LIQUID PREPARATIONS FOR INTERNAL USE}Underwear Liquid Formulation {LIQUID PREPARATIONS FOR INTERNAL USE}

본 발명은 용담과의 월년초(이하, 단순히 월년초라고도 한다)는 추출물의 약효성분이 장기간 안정하게 보관 유지되는 내복 액상 제제에 관한 것이다.The present invention relates to an oral liquid formulation in which the medicinal component of the extract is stably maintained for a long time.

생약인 용담과의 월년초(Swertia herba)는 Swertia japonia Makino의 개화기의 전초(全草)이고, 고미 건위약으로 분류되며, 위 카타르, 위산과다, 식욕 부진 등에 약효를 가진다. 당해 용담과의 월년초에는 쓴 맛 배당체인 스웨르티아마린(Swertiamarin) 외, 스웨르티아노린, 에리쓰로센타우린, 스웨르토리아노, 올레아놀산, 겐티아닌(gentianine) 등이 포함되어 있다.Swertia herba is the outpost of the flowering period of Swertia japonia Makino. It is classified as Gourmet Stomach, and has effects on stomach catarrh, hyperacidity and loss of appetite. In the beginning of the month of the gentian, Swertiamarin, which is a bitter glycoside, includes swertianarin, erythrosentaurin, swertoriano, oleanoic acid, and gentianine.

이러한 월년초 등의 건위생약을 배합한 제제로서는 종래부터 분말 제제, 가루약, 정제 등이 알려져 있지만, 근년, 복용 후의 흡수가 빠르고, 즉효성이 기대할 수 있는 것으로부터, 내복 액상 제제가 출시되고 있다.Powder formulations, powdered medicines, tablets and the like are conventionally known as formulations containing such hygiene medicines such as the beginning of the month. However, in recent years, an oral liquid formulation has been released since the absorption after taking the drug is fast and immediate effect can be expected.

그러나, 월년초 추출물을 내복 액상 제제에 배합하면, 경시적으로 그의 약효성분의 하나인 스웨르티아마린의 함량이 저하되는 것이 판명되었다.However, it has been found that, when the extract of early October, the extract is formulated into an internal liquid formulation, the content of swertiamarin, which is one of its active ingredients, decreases over time.

따라서, 본 발명의 목적은 장기간 안정하게 월년초 추출물을 유지한 내복 액상 제제를 제공하는 것이다.Accordingly, it is an object of the present invention to provide an oral liquid preparation having a long-term and stable extract of early spring.

본 발명자는 월년초 추출물의 함량 저하의 원인에 대해서, 온도, 농도, pH 등 여러 가지의 점으로부터 검토한 결과, 액상 제제 중에 있어서의 월년초 추출물중의 스웨르티아마린 함량의 경시안정성에 대해서는 pH가 극히 중요한 것, 더욱이 pH를 4∼7에 조정하면 해당 스웨르티아마린 함량의 경시안정성이 뛰어난 내복액상 제제를 얻을 수 있는 것을 발견하고, 본 발명을 완성하기에 이르렀다.The present inventors have investigated the causes of the content drop of the extract of early spring, from various points such as temperature, concentration, pH, and the like. Is extremely important, and furthermore, by adjusting the pH to 4-7, it was found that an oral liquid formulation having excellent time stability of the swertia marine content was obtained, and thus, the present invention was completed.

즉, 본 발명은 월년초 추출물을 함유하고, pH가 4∼7로 조정된 내복 액상 제제를 제공하는 것이다.That is, the present invention is to provide an oral liquid formulation containing an extract of early spring and adjusting the pH to 4-7.

[발명을 실시하기 위한 최선의 형태]Best Mode for Carrying Out the Invention

본 발명의 내복 액상 제제는 고미 건위 성분인 월년초 추출물을 함유한다. 여기서, 월년초 추출물로서는 생약인 월년초로부터 물, 열수, 에탄올, 물-에탄올 혼액 등의 용매로 추출한 추출물이 이용되지만, 물-에탄올 혼액에 의한 추출물이 특히 바람직하다.The oral liquid preparation of the present invention contains an extract of the herbaceous vinegar which is a bitter dry stomach ingredient. Here, as the extract of the early spring, an extract extracted with a solvent such as water, hot water, ethanol, and a water-ethanol mixture from a crude herbaceous extract, is used, but an extract by a water-ethanol mixture is particularly preferable.

월년초 추출물의 본 발명 내복 액상 제제중의 함유량은 1일 복용량으로서의 원 생약 환산량으로 5∼3000mg, 특히 10∼1500mg이 바람직하다.As for content of the extract of the extract of the beginning of the month of the present invention in the oral liquid formulation of this invention, 5-3000 mg, especially 10-1500 mg are preferable in conversion of original herbal as a daily dose.

본 발명 내복 액상 제제의 pH는 월년초 추출물중의 스웨르티아마린 함량의 경시 안정성의 점에서 4∼7인 것이 필요하고, 4.4∼6.3이 바람직하며, 4.5∼6.0이 보다 바람직하고, 4.8∼5.8이 특히 바람직하다.PH of the internal liquid liquid preparation of this invention needs to be 4-7 from the point of the stability with time of the swertiamarine content in the extract of the beginning of the month, 4.4-6.3 are preferable, 4.5-6.0 are more preferable, 4.8-5.8 This is particularly preferred.

pH를 4∼7에 조정하기 위하여는 이 범위의 pH로 하기 위한 완충제를 이용하는 것이 바람직하다. 이러한 완충제로서는 시트르산, 숙신산, 아세트산, 타르타르산, 염산, 황산, 글루콘산, 젖산, 푸말산, 붕산, 말레인산, 인산, 메탄술폰산, 말산, 이들의 염 등을 함유하는 완충제를 들 수 있으며, 이 중 특히, 시트르산, 시트르산 나트륨, 타르타르산, 타르타르산 나트륨, 말산, 말산 나트륨 등이 바람직하다. 이들 완충제는 pH를 상기 범위로 조정하는 양으로 배합된다. 또한, 이들의 산과 알칼리금속 수산화물, 특히 수산화나트륨을 병용하여 완충계로 하여도 좋다.In order to adjust pH to 4-7, it is preferable to use the buffer for making pH of this range. Such buffers include citric acid, succinic acid, acetic acid, tartaric acid, hydrochloric acid, sulfuric acid, gluconic acid, lactic acid, fumaric acid, boric acid, maleic acid, phosphoric acid, methanesulfonic acid, malic acid, salts thereof, and the like. , Citric acid, sodium citrate, tartaric acid, sodium tartarate, malic acid, sodium malate and the like are preferable. These buffers are combined in amounts to adjust the pH to the above range. Moreover, you may use together these acids and alkali metal hydroxide, especially sodium hydroxide as a buffer system.

본 발명 내복 액상 제제 중에는 월년초 추출물 이외의 약효성분을 배합하는 것이 할 수 있다. 이러한 약효성분으로서는 소화기계에 작용하는 약효성분이면 특히 제한되지 않으나, 예를 들면 아니스(Pimpinella anisum) 열매, 알로에, 회향(fennel fruit), 울금(turmeric), 오약(烏藥), 연명초(延命草), 황금, 황벽(黃蘗), 황련(黃連), 가공 마늘, 아술, 갈홍(葛洪), 모스퀴토 라미 루트(Mosquito Rami Root), 안피(雁皮), 지각(枳殼), 지실(枳實), 계피, 겐티아나(gentiana), 홍삼, 향목, 오수유(吳茱萸), 호숙, 카룸바 뿌리, 콘두란고(condurango), 산초, 산나(山奈), 페릴라에 프락투스(Perillae Fructus), 아모미 세멘(Amoni Semen), 생강, 소두구, 청피(靑皮), 석창근(石菖根), 센타우리움초, 창출, 페릴라에 헤르바(Perillae Herba), 대회향, 대황(大黃), 죽절인삼, 정자(丁子), 진피(陳皮),고추, 당회(唐檜), 동물 쓸개, 고목(苦木), 육두구, 인삼, 박하, 롱 페퍼(Long Pepper), 백출, 호프, 눅스 보미카(nux vomica), 조름나물(Buckbean), 목향, 알피니아에 프락투스(Alpiniae Fructus), 용담, 알피니아데 오피시나리 리초마(Alpiniae Officinari Rhizoma) 등의 건위생약의 추출물; 염산베타인, 글루타민산 염산염, 염화 카르니틴, 염화베타네콜, 건조 효모 등의 건위제; 건조 수산화알루미늄 겔, 규산 알루미늄산마그네슘, 규산마그네슘, 합성 규산알루미늄, 합성 히드로탈사이트, 산화마그네슘, 수산화 알루미나마그네슘, 수산화알루미늄겔, 수산화알루미늄·탄산수소나트륨 공침 생성물, 수산화알루미늄·탄산마그네슘 혼합 건조 겔, 수산화알루미늄·탄산마그네슘·탄산칼슘 공침 생성물, 수산화마그네슘, 탄산수소나트륨, 탄산마그네슘, 침강 탄산칼슘, 메타규산알루민산마그네슘, 무수 인산수소칼슘, 인산수소칼슘, 오징어뼈, 석결명(石決明), 오스트레아에 테스타(Ostreae Testa), 아미노아세트산, 디히드록시알루미늄 아미노아세테이트, 스코폴리아에 엑기스(Extractum Scopoliae) 등의 제산제; 전분소화효소, 단백소화효소, 지방 소화효소, 섬유소 소화효소, 우르소데스옥시콜산, 옥시콜란산염류, 콜산, 담즙분말, 담즙 엑기스(분말), 데히드로콜산, 동물쓸개 등의 소화제; 적아백(赤芽柏), 아선약(阿仙藥), 오매(烏梅), 결명자, 우편(牛扁) 등의 정장제; 아크리놀, 염화베르베린, 구아야콜, 크레오소트, 살리실산페닐, 탄산 구아야콜, 탄산베르베린, 탄닌산베르베린, 처살리실산 비스머스, 차질산비스머스, 차탄산비스머스, 차갈릭산비스머스, 탄닌산, 탄닌산알부민, 메틸렌티몰탄닌산, 카올린, 천연 규산알루미늄, 히드록시나프토에산알루미늄, 펙틴, 약용 숯, 침강 탄산칼슘, 젖산칼슘, 인산수소 칼슘, 아선약, 오매, 황벽, 황련, 고삼(苦參), 우편(牛扁), 오배자, 산사자(山査子), 미리카 바크(Myrica Bark) 등의 지사제; 염산 옥시펜사이클리민, 염산 디사이클로민, 염산 메티키센, 브롬화수소산스코폴라민, 브롬화 메틸아트로핀, 브롬화메틸아니소트로핀, 브롬화 메틸스코폴라민, 브롬화메틸 1-히요스시아민(1-hyscyamine methylbromide), 브롬화 메틸베낙티디움, 벨라돈나 엑기스, 요드화이소프로파미드, 요드화디페닐피페리디노메틸디옥소란, 스코폴리아에 엑기스, 스코폴리아에 뿌리 총알카로이드 시트르산염, 염산 파파베린, 아미노벤조산에틸, 엔코사크, 감초, 후박, 작약 등의 진통진경제; 아줄렌술폰산나트륨, 알디옥사(Aldioxa), 글리실리친산 및 그 염류 및 감초 추출물, L-글루타민, 동클로로필린칼륨, 동클로로필린나트륨, 염산 히스티딘, 돼지 위벽 펩신 분해물, 돼지 위벽 산가수분해물, 메틸메티오닌술폰뉴클로라이드, 적아백, 엔코삭, 감초 등의 점막 수복성분 등을 배합할 수 있다.In the internal liquid liquid formulation of the present invention, it is possible to mix medicinal ingredients other than the extract of early spring. The active ingredient is not particularly limited as long as it is an active ingredient that acts on the digestive system. For example, an aniseum (Pimpinella anisum) fruit, aloe, fennel fruit, turmeric, oak (오), yeonmyeongcho (延命) Green, golden, yellow wall, yellow lotus, processed garlic, azul, brown, mosquito Rami Root, skin, crust, ground Cinnamon, cinnamon, gentiana, red ginseng, safflower, sesame oil, lodging, carumbah root, condurango, sancho, sanna, perillae perillas fructus, Amoni Semen, Ginger, Soybean Paste, Cheongpi, Seok Geun Suk, Centaurium, Creation, Perillae Herba, Conventional Fragrance, Rhubarb, Bamboo Rice Ginseng, sperm, dermis, pepper, red pepper, animal gallbladder, dead tree, nutmeg, ginseng, peppermint, long pepper, white peach, hops, nox bomica nux vomica), Extracts of hygiene medicines such as Buckbean, Mokyang, Alpiniae Fructus, Gentian, Alpiniae Officinari Rhizoma, etc .; Healthy agents such as betaine hydrochloride, glutamic acid hydrochloride, carnitine chloride, betanechol chloride and dry yeast; Dry aluminum hydroxide gel, magnesium silicate, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium oxide, alumina magnesium hydroxide, aluminum hydroxide gel, aluminum hydroxide and sodium hydrogen carbonate coprecipitation product, aluminum hydroxide and magnesium carbonate mixed dry gel , Aluminum hydroxide, magnesium carbonate, calcium carbonate coprecipitation product, magnesium hydroxide, sodium bicarbonate, magnesium carbonate, precipitated calcium carbonate, magnesium metasilicate aluminate, anhydrous calcium phosphate, calcium hydrogen phosphate, squid bone, crystallization (石決明) Antacids such as Ostreae Testa, aminoacetic acid, dihydroxyaluminum aminoacetate, and Scopolia extract; Digestive agents such as starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, fibrin digestive enzyme, urodesoxycholic acid, oxycholates, cholic acid, bile powder, bile extract (powder), dehydrocholic acid and animal gallbladder; Formal preparations such as red bean bag, hyacinth medicine, omae, malaria, postal mail and the like; Acrinol, berberine chloride, guayacol, creosote, phenyl salicylate, guayacol carbonate, berberine carbonate, tannin berberine, chusalicylic acid bismuth, bismuth bismuth, bicarbonate bismuth, chagaric bismuth, tannic acid, Albumin tannin, methylene thimoltannic acid, kaolin, natural aluminum silicate, hydroxynaphthoate, aluminum pectin, medicinal charcoal, precipitated calcium carbonate, calcium lactate, calcium hydrogen phosphate, sun medicinal herbs, omega, yellow wall, yellow lotus, red ginseng Branch offices such as postal mail, offender, mountain lion and Myrica Bark; Oxyphene hydrochloride hydrochloride, Dicyclomine hydrochloride, Methiquicene hydrochloride, Scopolamine hydrobromide, methylatropine bromide, methylanisotropin bromide, methylscopolamine bromide, methyl bromide 1-hiyosciamine (1-hyscyamine methylbromide), methyl bromide bromide, belladonna extract, iodide propamide, iodide diphenylpiperidinomethyldioxolane, scofolia extract, scofolia root total alkaloid citrate, papaverine hydrochloride, amino Analgesic economics such as ethyl benzoate, encosac, licorice, humbac and peony; Sodium azulene sulfonate, Aldioxa, glycylic acid and its salts and licorice extracts, L-glutamine, copper chlorophyllin potassium, sodium chlorophyllin hydrochloride, histidine hydrochloride, pig gastric pepsin digest, pig gastric acid hydrolyzate, methyl Mucosal restorative components, such as methionine sulfone nuchloride, red eye bag, Enco sac, and licorice, etc. can be mix | blended.

또, 본 발명 내복 액상 제제에는 아스파라긴산 나트륨, 알긴산나트륨, 에데트산나트륨, 아황산나트륨, 아황산수소나트륨 등의 안정화제; 소르비톨, 백당 등의 감미제; 염화나트륨, L-글루타민산나트륨, 벌꿀, 사과 과즙 등의 교미제; 캬라멜 등의 착색제; l-멘톨, 민트 플래버, 체리 플래버 등의 향료, 레몬유, 오렌지유, 스피아민트유 등의 정유 등의 착향제; 벤조산나트륨, 파라옥시 벤조산부틸 등의 보존제; 폴리옥시에틸렌 경화 피마자기름, 에탄올 등의 용해 보조제 등을 배합할 수 있다.Moreover, the internal liquid liquid formulation of this invention contains stabilizers, such as sodium aspartate, sodium alginate, sodium edetate, sodium sulfite, sodium hydrogen sulfite; Sweeteners such as sorbitol and sucrose; Mating agents such as sodium chloride, sodium L-glutamate, honey, and apple juice; Coloring agents such as caramel; flavoring agents such as fragrances such as l-menthol, mint flavor and cherry flavor, and essential oils such as lemon oil, orange oil and spearmint oil; Preservatives such as sodium benzoate and butyl paraoxybenzoate; Dissolution aids, such as polyoxyethylene hardened castor oil and ethanol, etc. can be mix | blended.

본 발명 내복 액상 제제는 내복 액상 위장약으로서 유용하며, 통상 1회 복용량 20∼100㎖의 제제이며, 1일 1∼3회 복용하기 위한 제제로 하는 것이 바람직하다.The internal liquid liquid preparation of the present invention is useful as an internal liquid gastrointestinal drug, and is usually a one-dose dosage of 20 to 100 ml, and is preferably used as a preparation for taking one to three times a day.

실시예Example

다음에 실시예를 들어 본 발명을 더욱 상세하게 설명하지만, 본 발명은 이들에 하등 한정되는 것은 아니다.Although an Example is given to the following and this invention is demonstrated to it in more detail, this invention is not limited to these at all.

실시예 1∼ 12및 비교예 1, 2Examples 1 to 12 and Comparative Examples 1 and 2

표 1및 표 2에 나타낸 처방으로 월년초 추출액을 함유하는 내복 액상 제제를 제조했다.In the formulations shown in Table 1 and Table 2, an oral liquid formulation containing an early-month extract was prepared.

표중의 생약류는 아래와 같다.The herbal medicines in the table are as follows.

(1) 월년초 추출액(본품 1㎖는 원생약 1g에 상당한다. 추출용매: 에탄올 수용액)(1) Early spring extract (1 ml of this product is equivalent to 1 g of crude medicine. Extract solvent: ethanol aqueous solution)

(2) 생강 엑기스(본품 1㎖는 원생약 1g에 상당한다. 추출용매: 에탄올 수용액)(2) Ginger extract (1 ml of this product corresponds to 1 g of the original drug. Extraction solvent: ethanol aqueous solution)

(3) 인삼 엑기스(본품 1g는 원생약 4g에 상당한다. 추출용매: 에탄올 수용액)(3) Ginseng extract (1g of this product is equivalent to 4g of crude medicine. Extraction solvent: ethanol aqueous solution)

(4) 울금 엑기스(본품 1㎖는 원생약 1 g에 상당한다. 추출용매: 에탄올 수용액)(4) Turmeric extract (1 ml of this product is equivalent to 1 g of crude medicine. Extraction solvent: ethanol aqueous solution)

(5) 계피유(계피를 수증기 증류해 얻은 정유)(5) Cinnamon oil (essential oil obtained by steam distillation of cinnamon)

(6) 정자유(정자를 수증기 증류해 얻은 정유)(6) sperm oil (essential oil obtained by steam distillation of sperm)

(7) 회향유(회향을 수증기 증류해 얻은 정유)(7) Fennel oil (essential oil obtained by steam distillation of fennel)

또, 표 1 및 표 2에 나타낸 처방중의 성분량은 1변 30㎖중의 양을 나타내며, pH 조정은 시트르산과 수산화나트륨으로 행했다.In addition, the component amount in the prescription shown in Table 1 and Table 2 showed the quantity in 30 ml of one side, and pH adjustment was performed with citric acid and sodium hydroxide.

경시 안정성 시험Time stability test

실시예 1∼12 및 비교예 1, 2의 액상제제를 온도 70℃의 조건하에 3일간 보존한 후, 제제중의 스웨르티아마린의 잔존량을 고속 액체크로마토그래피로 정량했다.After the liquid formulations of Examples 1 to 12 and Comparative Examples 1 and 2 were stored for 3 days under conditions of a temperature of 70 ° C., the residual amount of swetithiamarin in the formulation was quantified by high performance liquid chromatography.

그 결과, 표 3에 나타난 바와 같이, 70℃라는 가혹한 조건에서도 pH 4∼7의 범위내에서는 월년초 추출물 함유 액상 제제중의 스웨르티아마린은 안정했다. 또, 70℃이라고 하는 가혹한 조건에서도 스웨르티아마린은 pH 4.4∼6.3의 범위내에서는 50%이상 잔존하고, pH 4.5∼6.0의 범위내에서는 60%이상 잔존하고, pH 4.8∼5.8의 범위내에서는 70%이상 잔존하고 있어 안정하였다.As a result, as shown in Table 3, even in the harsh conditions of 70 ° C, swyrthiamarin in the liquid formulation containing extract at the beginning of the year was stable within the range of pH 4-7. Further, even under severe conditions of 70 ° C, swertia marine remains 50% or more within the range of pH 4.4 to 6.3, 60% or more remains within the range of pH 4.5 to 6.0, and within the range of pH 4.8 to 5.8. It remained more than 70% and was stable.

본 발명의 내복 액상제제는 월년초 추출물중의 약효성분이 장기간 안정하게 유지되기 때문에 장기간 약효가 지속한다.The oral liquid preparation of the present invention lasts for a long time because the active ingredient in the extract of early January is stable for a long time.

Claims (2)

용담과 월년초 추출물을 함유하고, pH가 4∼7로 조정된 내복 액상 제제.An oral liquid formulation containing gentian and early spring extract, and having a pH adjusted to 4-7. 제 1항에 있어서, pH가 4.4∼6.3으로 조정된 내복 액상 제제.The oral liquid formulation according to claim 1, wherein the pH is adjusted to 4.4 to 6.3.
KR1020020050409A 2001-08-31 2002-08-26 Liquid preparations for internal use KR20030019902A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001264442A JP2003073291A (en) 2001-08-31 2001-08-31 Oral solution preparation
JPJP-P-2001-00264442 2001-08-31

Publications (1)

Publication Number Publication Date
KR20030019902A true KR20030019902A (en) 2003-03-07

Family

ID=19091038

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020050409A KR20030019902A (en) 2001-08-31 2002-08-26 Liquid preparations for internal use

Country Status (5)

Country Link
JP (1) JP2003073291A (en)
KR (1) KR20030019902A (en)
CN (2) CN1406625A (en)
HK (2) HK1053988A1 (en)
TW (1) TWI235663B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103995081A (en) * 2014-05-29 2014-08-20 杨增明 Application of 2,4,6-trihydroxy benzene acetophenone-3,5-di-C-beta-D-glucoside to quality detection of evodia lepta medicinal material

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4861753B2 (en) * 2006-06-20 2012-01-25 花王株式会社 Skin external composition
CN102397520B (en) * 2011-11-19 2013-12-04 西北农林科技大学 Oil-in-water compound star anise oil nanoemulsion oral liquid and preparation method thereof
CN105853275B (en) * 2016-04-26 2018-10-02 上海波林丝生物科技有限公司 A kind of formula of the natural plants component of generating hair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63190827A (en) * 1987-02-03 1988-08-08 Ota Isan:Kk Treating and preventive agent for ulcer and gastritis
JP3155271B2 (en) * 1989-08-03 2001-04-09 武田薬品工業株式会社 Yellow containing liquid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103995081A (en) * 2014-05-29 2014-08-20 杨增明 Application of 2,4,6-trihydroxy benzene acetophenone-3,5-di-C-beta-D-glucoside to quality detection of evodia lepta medicinal material

Also Published As

Publication number Publication date
TWI235663B (en) 2005-07-11
HK1053988A1 (en) 2003-11-14
HK1132190A1 (en) 2010-02-19
CN101518642A (en) 2009-09-02
JP2003073291A (en) 2003-03-12
CN1406625A (en) 2003-04-02
CN101518642B (en) 2010-07-14

Similar Documents

Publication Publication Date Title
KR0145739B1 (en) Effervescent tablet
JP2020512322A (en) Rapid and controlled delivery of compositions having a restored energetic effect
KR100893106B1 (en) Composition for promoting hair growth
KR20020087298A (en) Tonic composition comprising wild ginseng as main ingredient
ES2643716T3 (en) Novel formulations comprising herbaceous extracts
US20140295003A1 (en) Methods for improving health in canines
ITTO20010283A1 (en) COMPOSITION OF HERBS AND MANUFACTURING PROCEDURE OF SUCH COMPOSITION FOR THE TREATMENT OF GYNECOLOGICAL DISORDERS.
CN108938501A (en) Chinese medicine composition and oral care product applied to oral care product
KR100238565B1 (en) Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
JP2002087977A (en) Prophylactic, improving and therapeutic agent for hypertension
RU2737701C1 (en) Pharmaceutical composition of sedative and anxiolytic action
KR20030019902A (en) Liquid preparations for internal use
CN105031083B (en) Application of traditional Chinese medicine composition for preventing and treating oral ulcer in preparation of oral care product
JPH0491029A (en) Galenical drug blended chewable tablet
JPH0656677A (en) Antacid composition
US10245278B2 (en) Liquid or semi-liquid pharmaceutical, dietary or food composition free of bitterness containing an arginine salt
RU2240131C1 (en) Agent "artrovit" for prophylaxis and treatment of arthritis and arthrosis
JP2005023008A (en) Internal liquid medicine composition containing vitamin b group
KR20060090823A (en) Medicinal composition
CN101284069A (en) Chinese herbal medicine lozenge containing Chinese herbal medicine active composition for resisting helicobacter pylori and preparation method thereof
RU1826910C (en) Biostimulating agent
JPH07138279A (en) Stabilization of peoniphlorin
JP2003342186A (en) Oral liquid formulation composition for rhinitis
JP2019214622A (en) Oral composition
JP2021038155A (en) Climacteric symptom improver

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20081203

Effective date: 20090929